Two Ways to Highlight Your Startup at RESI in Paris

23 Jan

By Karen Deyo, Investor Research Analyst, LSN

On March 23rd, RESI will be coming to Paris for our second RESI in Europe. Life Science Nation (LSN) is offering early stage companies the chance to increase their exposure through two different startup showcases – the RESI Innovation Challenge and the new Featured Company Pitch Sessions.

Those who have attended RESI in the past are familiar with the RESI Innovation Challenge, which features the 30 most ‘investable’ companies, selected after a rigorous evaluation. These companies are evaluated based on innovativeness, marketability, stage of development and competitive edge, among other criteria, with selected companies presenting posters in the exhibit hall on the day of the conference. These companies compete for ‘investments’ of ‘RESI cash’ from their fellow attendees, with the top companies receiving prizes at the end of the day. Investors who attend RESI regularly are aware that companies selected to participate in the Innovation Challenge are selected based on merit, and many Innovation Challenge winners have successfully raised investments. The application deadline for the Innovation Challenge is February 21st, so make sure to apply here!

Meanwhile, the Featured Company Pitch Sessions are a new opportunity for companies to gain exposure to the investors attending RESI. For RESI Europe, companies can pay a fee of €1000 to pitch to a panel of investor judges as well as a broader audience of RESI attendees. Each hour slot will feature 4 companies pitching, with time after every pitch reserved for questions from the panel and audience. The application for the Featured Company Pitch Session is streamlined, with a rolling acceptance process. Pitching spots can fill up fast, so make sure to apply early.

Companies participating in both the Innovation Challenge and the Featured Company Pitch Sessions will be featured in the LSN Newsletter and the RESI Program Guide, with the Innovation Challenge winners announced after RESI.

 

RESI Innovation Challenge Featured Company Pitch Sessions
Rigorous application process, top 30 selected Streamlined application process, rolling acceptance
Poster display in the exhibit hall Pitch slot with 4 min pitch and 8 min Q&A
Competition with prizes Pitch to a dedicated feedback panel of investors
No fee to participate (beyond registration) Additional fee of €1000

Focus on Europe

23 Jan

By Gregory Mannix, Vice President International Business Development, LSN

At Life Science Nation we think that a strong and interconnected global ecosystem of life science strategic partners, investors and service providers will benefit the myriad entrepreneurs from around the globe in their quest to develop the latest technologies to treat and cure diseases. The fact that we took the Redefining Early Stage Investment (RESI) conference to Europe and Asia in 2019—for the first time outside of North America—is testament to this commitment.

Expanding the ecosystem to distant continents from our home base in Boston is a considerable challenge, but we think it’s worth it. We are making an effort to augment our contacts with major technology hubs in Europe and Asia in order to facilitate their emerging technologies joining the global ecosystem and accelerate their pathways to success.

In this context, LSN will be offering Fundraising Bootcamps in multiple cities in Europe in February. They are a chance for early-stage companies to learn about the fundraising ecosystem and the importance of honing their messaging to get the most traction with important partners. We hope you will be able to join us at one of our events. We would love to meet you!

Fundraising Bootcamp Schedule:

February 7th Oss (Netherlands) Info
February 10th Leiden (Netherlands) Info
February 24th Basel Info
February 25th Zurich Info
February 27th Barcelona Info

If you are a Tech Hub in Europe and would like to discuss hosting a Fundraising Bootcamp, please contact:

Greg Mannix (g.mannix@lifesciencenation.com)
Vice President International Business Development
Life Science Nation

 

RESI is Coming to Paris on March 23rd: Check Out the Panel Agenda Now

23 Jan

By Lucy Parkinson, VP of Investor Research, LSN

RESI’s first Europe event in 2019 was a lively gathering, with RESI’s ecosystem of global early stage investors and technologies coming together with life science startups and regional hubs from Europe and beyond.  RESI is now heading back to Europe for a Paris event on March 23rd.  We’re excited to be back, and we’ve put together a content agenda full of focused investor sessions on relevant topics for the occasion, including the return of our regional-focused Europe Tech Hubs panel. In addition, we will once again feature early stage investors sharing their perspectives on the investment landscape in core areas including Early Stage Therapeutic Investors, AI in Healthcare, and Diagnostics, and key partners will discuss their strategies in panels such as Big Pharma, Family Offices/Angels, and China Cross Border Partnerships. The content will also include workshops dedicated to helping entrepreneurs learn how to develop their investor marketing, valuation strategy and negotiation skills.  Our newest addition to the RESI Paris agenda is a full track of startup pitches, allowing companies to showcase their technologies in front of a panel of investors. Register here (link) for RESI Paris to see this content live and to meet one-on-one with investors in your space!

Hot Investor Mandate: Family Office Firm Invests Up to $20M with Strongest Interest in Clinical Stage Therapeutics and Devices with Large Market Potential

23 Jan

A private investment firm with offices in the USA is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border Investment Firm Seeks Seed to Series B Investment Opportunities Globally with Strong China Angle

23 Jan

A firm headquartered in China with an additional office in USA, is currently managing a venture capital fund in RMB with a total of 500 MM RMB (~70MM USD). The firm is currently focusing on the early-stage (from angel to series B) investments, with initial investment ranging from 3MM RMB (400,000 USD) to 5MM RMB (700,000 USD). The management team supports the firm with decades of experience in both the U.S. and China and is open to investing globally.

The firm has a general interest in the early-stage life science technology assets, especially therapeutics and medical devices. The fund also opens to diagnostics and healthcare IT, with the proven record of investing in hospital AI service platforms.

The firm prefers companies with China Angle, especially companies who are willing to register an entity/branch/joint venture in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Invests in Rare Disease Therapies and Diagnostics Globally

23 Jan

A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics and diagnostics to treat rare diseases.  The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Private Investment Firm Invests Up to $50M in Both Public & Private Companies with High Impact Investment Angle

23 Jan

A private investment partnership based in the USA is dedicated to providing impact investment capital to life science and healthcare companies in both public and private markets. The firm can invest from $1 – 50M depending on the stage of development of the company. The firm is open to global opportunities and has expertise with working in global markets.

The firm is most interested in therapeutics opportunities, and medical devices to a lesser extent. The firm looks for technologies that have the potential to make a significant impact to the global population. In therapeutics, the firm can look as early as pre-clinical to Phase I/IIa. For devices, the firm looks for those that are close to 510k FDA approval.

The firm invests in both publicly traded and privately owned companies. The firm prefers to work with experienced, transparent management teams with clearly demonstrated growth and defined (or capable of helping define) exit strategy. The firm prefers to lead and requires a board of directors seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: